ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1142

Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD

Sara Tedeschi1, Priyanka Kushwaha2, Muneet Gill2, Julia F. Charles3 and Ellen M. Gravallese4, 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 3Department of Orthopedic Surgery & Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

Meeting: ACR Convergence 2025

Keywords: bone biology, CPPD, Crystal-induced arthritis, osteoclast

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: CPPD has been associated with osteopenia of the metacarpal heads and a 2x increased risk for fracture of the wrist, hip, humerus or pelvis. Inorganic pyrophosphate is a known strong inhibitor of mineralization and a critical component of calcium pyrophosphate crystals. We conducted a pilot study testing for differences in tibial bone microstructure and histomorphometry in CPPD vs. controls.

Methods: Among patients undergoing total knee replacement surgery at a single academic medical center, we reviewed pre-operative radiographs for the presence of chondrocalcinosis in the knee, which defines the CPPD cohort. For each CPPD patient we identified one control matched on age (+/-5 years), sex, and race; controls were defined by absence of chondrocalcinosis on any joint radiograph. The tibial compartment analyzed (lateral or medial) was the same for each pair and was defined by the location of chondrocalcinosis in the CPPD patient and absence of Kellgren-Lawrence grade 4 in that compartment in both CPPD patients and controls. Microcomputed tomography (microCT) scanning was performed on formalin-fixed samples using a Scanco Medical mCT35 scanner with an isotropic voxel size of 20mm. A semi-automated contouring approach was used to exclude cortical bone and bone volume/tissue volume was calculated using software supplied by the manufacturer and a global threshold that set the bone/marrow cut-off at 398mg HA/cm3. Following decalcification and paraffin-embedding, trabeculae in the subchondral region were traced using Osteomeasure to determine bone surface area. TRAP staining identified osteoclasts (Oc) and Safranin O staining highlighted articular cartilage. Mean Oc surface/bone surface (Oc.S/BS) and Oc number/BS (Oc.N/BS) were calculated from 3 segments per sample.

Results: We obtained samples from 5 CPPD-control pairs (4 lateral compartment pairs, 1 medial compartment pair). Mean age was 69.6 (SD 9.5) years, 2 pairs were female, and all were White. Tibial plateau BV/TV was lower in samples from individuals with CPPD than controls (p=0.09) (Figure 1). Histomorphometry was performed for 2 pairs; analysis of the 3 remaining pairs is ongoing. Oc.S/BS and Oc.N/BS were higher in tibial plateau subchondral trabecular bone from individuals with CPPD than controls (Table 1, Figure 2).

Conclusion: Tibial plateau trabecular bone had lower BV/TV and more abundant osteoclasts in knee compartments with chondrocalcinosis among patients undergoing knee replacement surgery. These preliminary findings are directionally consistent with prior cohort studies that reported a greater risk of osteopenia and fractures in CPPD, and suggest a link between localized inorganic pyrophosphate and compromised bone microstructure.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: S. Tedeschi: Alexion, 5, Amgen, 2, Avalo Therapeutics, 2, Fresenius Kabi, 2, Kyowa Kirin, 2, Merck/MSD, 2, Novartis, 2; P. Kushwaha: None; M. Gill: None; J. Charles: Alexion, 2, 5, Kyowa Kirin, 2, Merck Manuals, 12, Authorship, UpToDate, 12, Authorship; E. Gravallese: Beam Therapeutics, 11, CRISPR Therapeutics, 11, Editas Medicine, 11, Elsevier, 9, Ginkgo Bioworks, 11, Intellia Therapeutics, 11, New England Journal of Medicine, 1, UpToDate, 9.

To cite this abstract in AMA style:

Tedeschi S, Kushwaha P, Gill M, Charles J, Gravallese E. Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/tibial-bone-microstructure-and-histomorphometry-in-individuals-with-cppd/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tibial-bone-microstructure-and-histomorphometry-in-individuals-with-cppd/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology